TrialsgrambetaRCTs are beautiful

ZENITH

2025

Sotatercept in High-Risk Pulmonary Arterial Hypertension

In 172 patients with high-risk pulmonary arterial hypertension, sotatercept reduced death, lung transplantation or heart-failure hospitalisation compared with placebo.

Result

Efficacy: Death, lung transplant or PAH hospitalisationHR 0.24

Below 1 favours sotatercept, above 1 favours placebo.

Also reported: (76 % reduction in the primary composite).

Original publication
Subtopic
Activin signalling
Design
Double-blind RCT, stopped early
Relevance
Important: one of several pillars.
Source
Humbert M, et al. N Engl J Med. 2025;392(20):1987-2000.doi 10.1056/NEJMoa2415160

Discussion & critique

Confirmed a hard-outcome benefit in the sickest PAH patients (functional class III–IV). Small and stopped early, which can inflate the effect estimate.

Discussed in podcasts